Literature DB >> 25337230

Diagnostic value of survivin for malignant pleural effusion: a clinical study and meta-analysis.

Panwen Tian1, Yongchun Shen1, Chun Wan1, Ting Yang1, Jing An1, Qun Yi1, Lei Chen1, Tao Wang1, Ye Wang1, Fuqiang Wen1.   

Abstract

OBJECTIVE: To investigate the diagnostic accuracy of survivin for malignant pleural effusion (MPE).
METHODS: Pleural effusion samples were collected from 40 MPE patients and 45 non-MPE patients. Pleural levels of survivin were measured by ELISA. Literature search was performed in Pubmed and Embase to identify studies regarding the usefulness of survivin to diagnose MPE. Data were retrieved and the pooled sensitivity, specificity and other diagnostic indexes were calculated. The summary receiver operating characteristics (SROC) curve was used to determine the overall diagnostic accuracy.
RESULTS: The pleural levels of survivin were higher in MPE patients than non-MPE patients (844.17 ± 358.30 vs. 508.08 ± 169.58 pg/ml, P < 0.05), at a cut-off value of 683.2 pg/ml, the sensitivity and specificity were 57.50% and 88.89%, respectively. A total of six studies were included in present meta-analysis, the overall diagnostic estimates were: sensitivity 0.74 (95% CI: 0.59-0.85); specificity, 0.85 (95% CI: 0.79-0.89); positive likelihood ratio, 4.79 (95% CI: 3.48-6.61); negative likelihood ratio, 0.31 (95% CI: 0.19-0.50), and diagnostic odds ratio, 15.59 (95% CI: 7.69-31.61). The area under SROC curve was 0.86 (95% CI: 0.82-0.89).
CONCLUSION: Our study confirms that the pleural survivin plays a role in the diagnosis of MPE. More studies at a large scale should be performed to validate our findings.

Entities:  

Keywords:  Survivin; diagnosis; malignant pleural effusion; meta-analysis

Mesh:

Substances:

Year:  2014        PMID: 25337230      PMCID: PMC4203201     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  17 in total

1.  Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data.

Authors:  S D Walter
Journal:  Stat Med       Date:  2002-05-15       Impact factor: 2.373

2.  The diagnostic odds ratio: a single indicator of test performance.

Authors:  Afina S Glas; Jeroen G Lijmer; Martin H Prins; Gouke J Bonsel; Patrick M M Bossuyt
Journal:  J Clin Epidemiol       Date:  2003-11       Impact factor: 6.437

Review 3.  Malignant pleural effusions: a review.

Authors:  Justin M Thomas; Ali I Musani
Journal:  Clin Chest Med       Date:  2013-07-23       Impact factor: 2.878

Review 4.  Evaluating the adult with new-onset pleural effusion.

Authors:  Danielle Kruger
Journal:  JAAPA       Date:  2013-07

Review 5.  Survivin beyond physiology: orchestration of multistep carcinogenesis and therapeutic potentials.

Authors:  Kalliopi Ch Athanasoula; Helen Gogas; Katerina Polonifi; Aristeidis G Vaiopoulos; Aristidis Polyzos; Marina Mantzourani
Journal:  Cancer Lett       Date:  2014-02-19       Impact factor: 8.679

6.  Evaluation of pleural fluid survivin and XIAP for the diagnosis of malignant pleural effusion.

Authors:  Jian Li; Zhen-Nan Li; Qian-Lei Bao; Li-Ping Ge; Xiao-Qin Li; Ping Chen
Journal:  Tumour Biol       Date:  2012-06-14

7.  Quantitative detection of survivin in malignant pleural effusion for the diagnosis and prognosis of lung cancer.

Authors:  Yao-Kuang Wu; Kuei-Tien Chen; Yung-Bin Kuo; Ya-Shu Huang; Err-Cheng Chan
Journal:  Cancer Lett       Date:  2008-09-27       Impact factor: 8.679

8.  Immunohistochemical expression of nuclear and cytoplasmic survivin in gastrointestinal carcinoma.

Authors:  Michiko Shintani; Akiko Sangawa; Naoki Yamao; Shingo Kamoshida
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

Review 9.  Recommendations of diagnosis and treatment of pleural effusion. Update.

Authors:  Victoria Villena Garrido; Enrique Cases Viedma; Alberto Fernández Villar; Alicia de Pablo Gafas; Esteban Pérez Rodríguez; José Manuel Porcel Pérez; Francisco Rodríguez Panadero; Carlos Ruiz Martínez; Angel Salvatierra Velázquez; Luis Valdés Cuadrado
Journal:  Arch Bronconeumol       Date:  2014-03-31       Impact factor: 4.872

Review 10.  Can cholesterol be used to distinguish pleural exudates from transudates? evidence from a bivariate meta-analysis.

Authors:  Yongchun Shen; Hong Zhu; Chun Wan; Lei Chen; Tao Wang; Ting Yang; Fuqiang Wen
Journal:  BMC Pulm Med       Date:  2014-04-15       Impact factor: 3.317

View more
  2 in total

1.  Role of cancer ratio and other new parameters in the differential diagnosis of malignant pleural effusion.

Authors:  Zenghua Ren; Ling Xu
Journal:  Clinics (Sao Paulo)       Date:  2021-04-26       Impact factor: 2.365

2.  Validation of Calprotectin As a Novel Biomarker For The Diagnosis of Pleural Effusion: a Multicentre Trial.

Authors:  Maribel Botana-Rial; Lorena Vázquez-Iglesias; Pedro Casado-Rey; María Páez de la Cadena; María Amalia Andrade-Olivié; José Abal-Arca; Laura García-Nimo; Lucía Ferreiro-Fernández; Luis Valdés-Cuadrado; María Esther San-José; Francisco Javier Rodríguez-Berrocal; Alberto Fernández-Villar
Journal:  Sci Rep       Date:  2020-03-30       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.